Giredestrant combination significantly improved PFS in ER-positive advanced breast cancer in Ph 3 evERA; data published in The NEJM October 6, 2026
Epcoritamab + R-CHOP combo Demonstrates Significant PFS Improvement versus R-CHOP in 1L DLBCL Patients October 6, 2026
Results from VIRAGE Ph 2b Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine October 6, 2026
Positive topline results from Ph 3 AZTOUND trial of oral azacitidine and cedazuridine (ASTX030) in MDS and CMML patients announced October 6, 2026
RD140 achieved ~89% ORR & MRD negativity rate in heavily pretreated, high-risk RRMM or plasma cell leukemia patients October 6, 2026
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) October 6, 2026
Rinatabart Sesutecan (Rina-S®) Ph 2 RAINFOL™-01 Results Demonstrate Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer October 6, 2026
Results Announced for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Ph 3 EXCALIBER-RRMM Trial in RRMM Patients October 1, 2026
Nature Medicine Publication of ASPEN-06 Ph 2 Data Demonstrates Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer October 1, 2026
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line RRMM October 1, 2026
VERSATILE-002 Ph 2 Results of PDS0101 + pembrolizumab in HPV16+ve Recurrent and/or Metastatic (R/M) Head & Neck Cancer published in JAMA Oncology October 1, 2026
Final OS results from randomized Ph 2 OVATION 2 Study of IMNN-001 in IL advanced ovarian cancer October 1, 2026
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line RRMM October 1, 2026
New Analyses Reinforcing Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC Announced September 22, 2026
Lunsumio-based regimen significantly improves PFS in follicular lymphoma in Ph 3 CELESTIMO study September 22, 2026
Complete Full Cohort Ph 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent NSCLC Announced September 22, 2026
GX-BP1 Suppresses Tumor Regrowth despite Osimertinib and Dato-DXd Combination and Achieves 6/6 Complete Responses in Triple Combination September 22, 2026
Updated Data from Ph 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of BH-30643 in EGFR C797S-Positive NSCLC Presented September 22, 2026
Gotistobart Nearly Doubled Median OS versus SOC Chemo in Previously Treated Squamous NSCLC Patients September 16, 2026
Zipalertinib + chemo Demonstrates 6-Month Median PFS Benefit in REZILIENT3 Ph 3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC September 16, 2026
